

# SUSTAINABLE INHALER ALTERNATIVES

Cost and coverage for asthma and COPD inhalers in British Columbia



This version has been modified by the Interior Health MDI Pilot Project Team (2024)

Least Environmentally Preferable      Less Environmentally Preferable      More Environmentally Preferable

**Do not FORCE inhaler switches**  
Can result in lack of control, exacerbations, and further emissions.

## Reliever Therapy

**Ventolin salbutamol**

100mcg: ~\$19

**MDI**

**Teva salbutamol**      **Airomir salbutamol**

100mcg: ~\$18      100mcg: ~\$18

**Low Volume MDIs**

**Bricanyl Turbuhaler terbutaline**      **Ventolin Diskus salbutamol**      **Symbicort Turbuhaler budesonide/formoterol**

0.5mg: ~\$24      200mcg: ~\$25      200/6: ~\$115

**Dry-Powder Inhalers (DPIs)**

## ICS Maintenance

**Qvar beclomethasone**      **Flovent fluticasone**      **Alvesco ciclesonide**

50mcg: ~\$55      125mcg: ~\$70      100mcg: ~\$70  
100mcg: ~\$100      250mcg: ~\$130      200mcg: ~\$105

**Metered Dose Inhalers (MDIs)**

**Pulmicort Turbuhaler budesonide**      **Aermony Resplick fluticasone propionate**      **Asmanex Twisthaler mometasone**      **Flovent Diskus fluticasone propionate**      **Arnuity Ellipta fluticasone furoate**

100mcg: ~\$50      113mcg: ~\$50      200mcg: ~\$55      250mcg: ~\$70      100mcg: ~\$65  
200mcg: ~\$95      232mcg: ~\$70      400mcg: ~\$100      500mcg: ~\$100      200mcg: ~\$110  
400mcg: ~\$130

**Dry-Powder Inhalers (DPIs)**

## ICS/LABA

**Zenhale mometasone/formoterol**      **Advair fluticasone propionate/salmeterol**

100/5: ~\$125      125/25: ~\$140  
200/5: ~\$150      250/25: ~\$195

**MDIs**

**Wixela InHub fluticasone propionate/salmeterol**      **Advair Diskus fluticasone propionate/salmeterol**      **Symbicort Turbuhaler budesonide/formoterol**      **Breo Ellipta fluticasone furoate/vilanterol**      **Atectura Breezhaler mometasone/indacaterol**

100/50: ~\$65      100/50: ~\$120      100/6: ~\$90      100/25: ~\$120      80/150: ~\$50  
250/50: ~\$70      250/50: ~\$140      200/6: ~\$115      200/25: ~\$185      160/150: ~\$60  
500/50: ~\$95      500/50: ~\$195

**Dry-Powder Inhalers (DPIs)**

**LABA, LAMA, and LABA/LAMA inhalers are currently only available as DPIs or soft-mist inhalers (SMIs), so they are already environmentally preferable!**

- |                           |                           |
|---------------------------|---------------------------|
| <b>Anoro Ellipta</b>      | <b>Seebri Breezhaler</b>  |
| <b>Duaklir Genuair</b>    | <b>Serevent Diskus</b>    |
| <b>Incruse Ellipta</b>    | <b>Spiriva Handihaler</b> |
| <b>Inspiolto Respimat</b> | <b>Spiriva Respimat</b>   |
| <b>Onbrez Breezhaler</b>  | <b>Tudorza Genuair</b>    |
| <b>Oxeze Turbuhaler</b>   | <b>Ultibro Breezhaler</b> |

## Triple Therapy

**Breztri Aerosphere budesonide/formoterol/glycopyrronium**

182/5.8/8.2 ~ \$160

**MDI**

**Trelegy Ellipta fluticasone/umeclidinium/vilanterol**      **Enerzair Breezhaler mometasone/glycopyrronium/indacaterol**

100/62.5/25      150/50/160  
COPD      SA      SA  
200/62.5/25      SA      SA  
ASTHMA X

100/62.5/25: ~\$175      150/50/160 ~ \$135  
200/62.5/25: ~\$190

**DPIs**

This project was undertaken with the financial support of the Government of Canada. Ce projet a été réalisé avec l'appui financier du gouvernement du Canada.



All costs based on [Drugsearch.ca](http://Drugsearch.ca) as of May 2023, costs may vary. Adapted from The CARE Project, Hamilton Family Health Team, and Cascades Canada Sustainable Inhaler Alternatives BC chart (see [CascadesCanada.ca](http://CascadesCanada.ca)) This resource does not reflect all available meds or all information, read product monograph before prescribing. This version is also shared under a Creative Commons attribution, non-commercial, share-alike licence (CC BY-NC-SA 4.0)

Regular Benefit

Not a Benefit

Asthma Special Authority

COPD Special Authority

On Interior Health Formulary

Diagnosis of asthma AND inadequate response on optimal dose of inhaled corticosteroid, approval period indefinite.

\* Diagnosis of asthma, inadequate response with a maintenance combination of an optimal dose of long-acting beta-2 agonist (LABA) AND a moderate to high dose of an inhaled corticosteroid AND experienced one or more asthma exacerbations in the previous 12 months.

Diagnosis of moderate to very severe COPD based on FEV1 and FVC.

